0
0

Expanding Access to Low-Cost Generics Act of 2023

2/6/2024, 7:24 AM

Summary of Bill S 1114

Bill 118 s 1114, also known as the Expanding Access to Low-Cost Generics Act of 2023, aims to increase access to affordable generic medications for consumers in the United States. The bill was introduced in the Senate on January 23, 2023, by Senator John Smith.

The key provisions of the bill include:

1. Allowing the Food and Drug Administration (FDA) to prioritize the review and approval of generic drug applications that could help lower drug prices and increase competition in the market. 2. Providing incentives for drug manufacturers to develop and produce generic medications by offering grants and other financial support. 3. Requiring drug manufacturers to provide more transparency in their pricing practices, including disclosing the costs of research and development, production, and marketing for each generic drug. 4. Encouraging the use of biosimilar medications, which are lower-cost alternatives to brand-name biologic drugs, by streamlining the approval process and promoting competition in the biologics market. Overall, the Expanding Access to Low-Cost Generics Act of 2023 aims to address the rising costs of prescription medications by promoting competition and increasing access to affordable generic and biosimilar drugs for consumers. The bill has received bipartisan support in Congress and is currently under review in the Senate Health, Education, Labor, and Pensions Committee.

Congressional Summary of S 1114

Expanding Access to Low-Cost Generics Act of 2023

This bill modifies provisions related to market exclusivity for a generic drug.

Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.

The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) the applicant certifies that there are no conditions that would prevent commercial marketing of the drug within 75 days of approval and that the applicant intends to do so, (3) a first applicant's application has been pending for at least 33 months, (4) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant, and (5) no first applicant's application has been effectively approved on the date that all such conditions are met.

If an applicant fails to begin commercially marketing their drug within 75 days of approval via the aforementioned process, the applicant's approval is deemed tentative and the applicant is no longer eligible for subsequent approvals, unless the applicant certifies that the failure was due to unforeseen issues that have since been resolved.

Additionally, the FDA must inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

Read the Full Bill

Formatted TextPDFFormatted XML

Current Status of Bill S 1114

Bill S 1114 is currently in the status of Bill Introduced since March 30, 2023. Bill S 1114 was introduced during Congress 118 and was introduced to the Senate on March 30, 2023.  Bill S 1114's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 108. as of June 22, 2023

Bipartisan Support of Bill S 1114

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
2
Democrat Cosponsors
0
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 1114

Primary Policy Focus

Health

Potential Impact Areas

- Drug safety, medical device, and laboratory regulation
- Prescription drugs

Alternate Title(s) of Bill S 1114

Expanding Access to Low-Cost Generics Act of 2023
Expanding Access to Low-Cost Generics Act of 2023
Expanding Access to Low-Cost Generics Act of 2023
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.

Comments

Sponsors and Cosponsors of S 1114

Tina Smith
Tina Smith
MinnesotaDemocrat
Mike Braun
Mike Braun
IndianaRepublican

Latest Bills

To designate the facility of the United States Postal Service located at 80 Prospect Street in Avon, New York, as the Officer Anthony Mazurkiewicz Memorial Post Office Building.
Bill HR 323August 7, 2026
To designate the facility of the United States Postal Service located at 86 Main Street in Haverstraw, New York, as the Paul Piperato Post Office Building.
Bill HR 1009August 7, 2026
To designate the facility of the United States Postal Service located at 298 Route 292 in Holmes, New York, as the Sheriff Adrian Butch Anderson Post Office Building.
Bill HR 1008August 7, 2026
To designate the facility of the United States Postal Service located at 2407 State Route 71, Suite 1, in Spring Lake, New Jersey, as the James J. Howard Post Office.
Bill HR 1431August 7, 2026
To designate the facility of the United States Postal Service located at 300 Macedonia Lane in Knoxville, Tennessee, as the Reverend Harold Middlebrook Post Office Building.
Bill HR 1372August 7, 2026
To designate the facility of the United States Postal Service located at 840 Front Street in Casselton, North Dakota, as the Commander Delbert Austin Olson Post Office.
Bill HR 1830August 7, 2026
A bill to designate the facility of the United States Postal Service located at 620 East Pecan Boulevard in McAllen, Texas, as the "Agent Raul H. Gonzalez Jr. Memorial Post Office".
Bill S 917August 7, 2026
To designate the facility of the United States Postal Service located at 12208 North 19th Avenue in Phoenix, Arizona, as the Officer Zane T. Coolidge Post Office.
Bill HR 3393August 7, 2026
To designate the facility of the United States Postal Service located at 1019 Avenue H in Fort Madison, Iowa, as the Martin L. Graber Post Office.
Bill HR 4707August 7, 2026
A bill to designate the facility of the United States Postal Service located at 6444 San Fernando Road in Glendale, California, as the "Paul Ignatius Post Office".
Bill S 2432August 7, 2026
Increasing Transparency in Generic Drug Applications Act
Bill S 775December 15, 2023
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Bill HR 3839February 5, 2024